Browse products

Related products

more on pharma »
more on Central and Eastern Europe »

OTC market in Central and Eastern Europe 2011

Comparative analysis and development forecasts for 2011-2013
OTC market in Central and Eastern Europe 2011 Comparative analysis and development forecasts for 2011-2013

October 2011
Pages: 341
Delivery: PDF


Our clients say... 
“PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales. ” Market Analyst, Alpha Cement
“As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding.” Development Manager, GVA Grimley
“PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. ” Senior Trade and Investment Adviser, British Embassy in Warsaw
“PMR provides a good service and is always open to discussion. All reports are well structured & are always on time.” Member of the Managment Board, SCA Hygiene Products
“We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis.” Senior Trade and Investment Adviser, British Embassy in Warsaw
“It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner.” Business Analyst, Hilti Distribution, Russia
“Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. ” General Manager, Sanofi-Synthelabo
“We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis.” General Manager, Sanofi-Synthelabo
The report is a complex analysis of OTC drug and dietary supplement markets in eight countries in the region:
  • Russia
  • Poland
  • Ukraine
  • Romania
  • the Czech Republic
  • Hungary
  • Bulgaria
  • Slovakia.
It analyses the market value in particular countries, as well as in the whole CEE region and pays particular attention to such information as OTC drug market value, dietary supplement market value, share of OTC in the total market, best-selling OTC products, leading OTC manufacturers, and non-pharmacy and online sales of OTC products.
The publication also contains forecasts up to 2013 for OTC drug/product markets in particular countries as well as for the whole region, prepared by a team of pharmaceutical market analysts and PMR’s economy experts. The report is complemented with the analysis of distribution segments in particular countries. It is a unique publication which presents all the important information regarding the OTC product market in the CEE region on more than 300 pages.

Key topics covered:

Did you know... 
“There has recently been much discussion on the availability of OTC medicines in Russia.”
“All pharmacy kiosks in Ukrainian cities will have to disappear.”
“Since August 2011, 10 anti-inflammatory ointments containing ketoprofen have been sold in Romania only on prescription.”
“Attitudes to dietary supplements in Russia are still ambiguous.”
“The prospects for growth on the Bulgarian OTC market remain very good.”
“In August 2011 Polish Laboratoria Natury was bought by Maabarot Products.”
“The number of dietary supplement notifications in Hungary rose rapidly in 2010.”
  • best selling OTC drugs in individual countries
  • best selling dietary supplements in individual countries
  • leading OTC drug manufacturers in individual countries
  • profiles of leading regional OTC manufacturers
  • leading dietary supplement manufacturers in individual countries
  • OTC drug market value 2007-2013 in individual countries
  • dietary supplements market value in individual countries
  • share of OTC in total pharmacy sales in individual countries
  • sales structure of OTC products in pharmacy sales in individual countries
  • regulations regarding non-pharmacy sales of OTC products in individual countries
  • regulations regarding online sales of OTC products in individual countries
  • largest advertisers in the OTC segment in individual countries
  • largest pharmacy chains in individual countries
  • largest wholesalers in individual countries
  • main events and trends in individual countries
  • comparative analysis of OTC market value, share of OTC as a proportion of the entire market and share of dietary supplements as a proportion of the entire market
  • consumer behaviours regarding OTC product intake in individual countries
  • epidemiological trends.

When will the report prove useful?

  • when starting a business on the OTCmarket in CEE
  • when developing OTC products sales in CEE
  • when analysing competitors
  • when analysing the market saturation
  • when developing OTC products portfolio in a particular CEE country.

Report strengths:

  • all information regarding the OTC products segment in CEE in one place
  • comparative analysis of OTC product markets in 8 countries
  • the report provides broad range of historical data as it is its third edition
  • development forecasts for 2011-2013.

Find answers for the following questions:

  • In which country is  the OTC market the largest?
  • In which country has the OTC market the highest growth potential?
  • Which CEE country has the “friendliest” environment for OTC products?
  • In which country is the OTC market  profoundly saturated?
  • What are the strategies OTC manufacturers introduce into the market in CEE?

This report is adressed to:

  • the senior management of OTC companies active in the region
  • pharmaceutical wholesalers and distributors
  • non-pharmacy and on-line drug distributors
  • research and analytical institutions 
  • embassies and other government institutions.

Companies mentioned in this report:

Actavis, Akvion, Bayer, Beres, Berlin-Chemie/Menarini, Boehringer Ingelheim, Bristol-Myers Squibb, Diod, Evalar, Farmak, Gedeon Richter, GlaxoSmithKline, Johnson & Johnson, Maspex, Novartis, NP Pharma, Ozone Laboratories, Pfizer, Pharmstandard, Reckitt Benckiser, RIA Panda, Sandoz, Sanofi, Sopharma, Stada, Teva, US Pharmacia, Walmark.

Extract from this report

  • According to our forecasts, in the next three years the most attractive of the analysed markets in the region, taking into account forecasted market growth, will be Bulgaria.
  • According to our forecasts, in 2011 the OTC market in Central and Eastern Europe will grow by close to 10% in real terms. In 2012 it will see a positive growth rate of more than 9%, whereas in 2013 it will expand by around 8%.

Market commentary by expert

According to our estimates, in 2010 the OTC market in the CEE region was worth some €10.7bn, which represented an increase of approx. 13% y-o-y in euro terms. A half was generated by Russia. In 2010, Poland was the second largest OTC market in the region, with a share in total sales of around 23%. Ukraine accounted for around 7% of all OTC business on the CEE market. According to our forecasts, between 2011 and 2013 the market will expand by around 9% on average per annum. Bulgaria and Ukraine will be the fastest developing markets in the region in the analysed period. 
Agnieszka Skonieczna, Pharmaceutical Market Analyst

Request sample pages/interactive screenshare

To receive more information on this report, please sign up.

*required

*Would you like a FREE
interactive screenshare?
*Email:
To make sure you receive the requested information, add info@pmrcorporate.com to your company trusted emails. Contact your IT department for details.
*Your company core business:

Privacy Policy

  1. Report methodology p. 15

  2. Executive summary p. 21

  3. OTC market in CEE countries p. 23

    • Comparative analysis of OTC markets in CEE region p. 23
      • Share of individual OTC markets in 2010 p. 23
      • Per capita OTC spending in CEE countries p. 24
      • Value of OTC market in CEE countries 2008-2013 p. 25
      • Average CAGR for OTC markets in CEE countries 2009-2010 and 2011-2013 p. 25
    • Russia p. 26
      • Main trends and events on OTC market p. 26
      • OTC market value p. 30
        • OTC market value by distribution channel p. 30
        • OTC market value by product status (drugs vs. dietary supplements) p. 30
        • Share of OTC as a proportion of the pharmaceutical market p. 31
        • Value of OTC drug market between 2008 and 2013 p. 33
        • Value of dietary supplement market between 2008 and 2013 p. 34
        • OTC product market by therapeutic category p. 36
      • Prices of OTC products p. 38
      • Best-selling OTC products p. 39
    • Poland p. 42
      • Main trends and events on OTC market p. 42
      • OTC market value p. 48
        • OTC market value by distribution channel p. 48
        • OTC market value by product status (drugs vs. dietary supplements) p. 50
        • Share of OTC as a proportion of the pharmaceutical market p. 50
        • Value of OTC product market between 2008 and 2013 p. 51
        • Value of dietary supplement market p. 51
        • OTC products market by therapeutic category p. 52
      • Prices of OTC products p. 56
      • Switch from Rx to OTC p. 57
      • Best-selling OTC products p. 58
    • Ukraine p. 59
      • Main trends and events on OTC market p. 59
      • OTC market value p. 65
        • OTC market value by product status (drugs vs. dietary supplements) p. 65
        • Share of OTC as a proportion of the pharmaceutical market p. 68
        • Value of OTC drug market between 2008 and 2013 p. 68
        • Value of dietary supplement market between 2008 and 2013 p. 69
      • Prices of OTC products p. 71
      • Switch from Rx to OTC p. 74
      • Best-selling OTC products p. 74
    • Czech Republic p. 78
      • Main trends and events on OTC market p. 78
      • OTC market value p. 83
        • OTC market value by distribution channel p. 83
        • OTC drug market by volume p. 84
        • Share of OTC as a proportion of the pharmaceutical market p. 84
        • Value of OTC product market between 2008 and 2013 p. 85
        • Value of dietary supplement market p. 85
        • OTC product market by therapeutic category p. 85
      • Prices of OTC products p. 86
      • Switch from Rx to OTC p. 87
      • Best-selling OTC products p. 87
    • Romania p. 88
      • Main trends and events on OTC market p. 88
      • OTC market value p. 93
        • OTC market value by distribution channel p. 93
        • OTC market value by product status (drugs vs. dietary supplements) p. 93
        • Share of OTC as a proportion of the pharmaceutical market p. 93
        • Value of OTC product market between 2006 and 2013 p. 94
        • Value of dietary supplement market between 2005 and 2013 p. 95
        • OTC drug market by therapeutic category p. 96
      • Prices of OTC products p. 96
      • Switch from Rx to OTC p. 97
      • Best-selling OTC products p. 97
    • Hungary p. 98
      • Main trends and events on OTC market p. 98
      • OTC market value p. 102
        • OTC market value by distribution channel p. 102
        • OTC market value by product status (drugs vs. dietary supplements) p. 104
        • Share of OTC as a proportion of the pharmaceutical market p. 105
        • Value of OTC product market between 2008 and 2013 p. 105
        • Value of dietary supplement market p. 106
        • OTC drug market by therapeutic category p. 106
      • Prices of OTC products p. 108
      • Switch from Rx to OTC p. 110
      • Best-selling OTC products p. 110
    • Bulgaria p. 112
      • Main trends and events on OTC market p. 112
      • OTC market value p. 114
        • OTC market value by distribution channel p. 114
        • OTC market value by product status (drugs vs. dietary supplements) p. 116
        • Share of OTC as a proportion of the pharmaceutical market p. 117
        • Value of OTC product market between 2009 and 2013 p. 117
        • Value of dietary supplement market p. 118
        • OTC drug market by therapeutic categories p. 119
      • Prices of OTC products p. 119
      • Best-selling OTC products p. 121
    • Slovakia p. 123
      • Main trends and events on OTC market p. 123
      • OTC market value p. 127
        • OTC market value by distribution channel p. 127
        • Share of OTC as a proportion of the pharmaceutical market p. 127
        • Value of OTC product market between 2006 and 2012 p. 127
        • OTC drug market by therapeutic category p. 128
      • Prices of OTC products p. 129
      • Switch from Rx to OTC p. 130
      • Best-selling OTC products p. 130

  4. Advertising of OTC products in CEE countries p. 133

    • Russia p. 133
      • Legal framework p. 133
      • Spending on OTC advertising p. 134
    • Poland p. 137
      • Legal framework p. 137
      • Spending on OTC advertising p. 139
        • TV advertising p. 140
        • Radio advertising p. 141
        • Internet advertising p. 142
        • Outdoor advertising p. 142
    • Ukraine p. 143
      • Legal framework p. 143
      • Spending on OTC advertising p. 144
        • TV advertising p. 145
        • Radio advertising p. 147
        • Press advertising p. 148
        • Internet advertising p. 148
    • Czech Republic p. 149
      • Legal framework p. 149
      • Spending on OTC advertising p. 150
        • TV advertising p. 152
        • Radio advertising p. 153
        • Press advertising p. 153
        • Advertising on other media p. 154
    • Romania p. 154
      • Legal framework p. 154
      • Spending on OTC advertising p. 155
    • Hungary p. 156
      • Legal framework p. 156
      • Spending on OTC advertising p. 157
    • Bulgaria p. 158
      • Legal framework p. 158
      • Spending on OTC advertising p. 158
    • Slovakia p. 159
      • Legal framework p. 159
      • Spending on OTC advertising p. 160

  5. Key manufacturers p. 161

    • Profiles of selected local manufacturers on OTC market in CEE p. 161
    • Key players in selected CEE countries p. 179
      • Russia p. 179
      • Poland p. 181
      • Ukraine p. 182
      • Czech Republic p. 186
      • Romania p. 188
      • Hungary p. 188
      • Bulgaria p. 189
      • Slovakia p. 191

  6. Distribution p. 193

    • Russia p. 193
      • Pharmaceutical wholesalers p. 193
        • Segment profile p. 193
        • Selected key players p. 195
      • Pharmacy distribution p. 201
        • Segment profile p. 201
        • Selected key players p. 202
      • Non-pharmacy sales p. 211
      • Online sales p. 211
    • Poland p. 212
      • Pharmaceutical wholesalers p. 212
        • Segment profile p. 212
        • Selected key players p. 213
      • Pharmacy distribution p. 218
        • Segment profile p. 218
        • Selected key players p. 221
      • Non-pharmacy sales p. 225
      • Online sales p. 226
    • Ukraine p. 228
      • Pharmaceutical wholesalers p. 228
        • Segment profile p. 228
        • Selected key players p. 229
      • Pharmacy distribution p. 235
        • Segment profile p. 235
        • Selected key players p. 236
      • Non-pharmacy sales p. 240
      • Online sales p. 241
    • Czech Republic p. 242
      • Pharmaceutical wholesalers p. 242
        • Segment profile p. 242
        • Selected key players p. 243
      • Pharmacy distribution p. 247
        • Segment profile p. 247
        • Selected key players p. 248
      • Non-pharmacy sales p. 253
      • Online sales p. 254
    • Romania p. 255
      • Pharmaceutical wholesalers p. 255
        • Segment profile p. 255
        • Selected key players p. 256
      • Pharmacy distribution p. 263
        • Segment profile p. 263
        • Selected key players p. 265
      • Non-pharmacy sales p. 275
      • Online sales p. 275
    • Hungary p. 276
      • Pharmaceutical wholesalers p. 276
        • Segment profile p. 276
        • Selected key players p. 277
      • Pharmacy distribution p. 281
        • Segment profile p. 281
        • Selected key players p. 283
      • Non-pharmacy sales p. 286
      • Online sales p. 287
    • Bulgaria p. 288
      • Pharmaceutical wholesalers p. 288
        • Segment profile p. 288
        • Selected key players p. 289
      • Pharmacy distribution p. 294
        • Segment profile p. 294
        • Selected key players p. 296
      • Non-pharmacy sales p. 298
      • Online sales p. 298
    • Slovakia p. 299
      • Pharmaceutical wholesalers p. 299
        • Segment profile p. 299
        • Selected key players p. 300
      • Pharmacy distribution p. 304
        • Segment profile p. 304
        • Selected key players p. 305
      • Non-pharmacy sales p. 307
      • Online sales p. 307
    • Comparative analysis of distribution in CEE p. 309
      • Non-pharmacy sales p. 309
      • Online sales p. 310
      • Pharmacy distribution p. 311

  7. Factors influencing OTC market in CEE countries p. 313

    • Macroeconomic and demographic indicators p. 313
      • GDP growth p. 313
      • Inflation rates p. 316
      • Labour market p. 317
        • Unemployment rates p. 317
        • Wage levels p. 318
      • Population p. 319
    • Epidemiological trends p. 319
      • Life expectancy at birth p. 319
      • Weight problems p. 320
      • Alcohol consumption p. 321
      • Smoking prevalence p. 323

  8. List of graphs p. 325

  9. List of tables p. 337

  10. About PMR p. 339

List of graphs

  1. Share of individual OTC markets as a proportion of total OTC market in CEE, 2010      21
  2. Value (€ bn) and y-o-y change of the OTC products market in CEE, 2008-2013      22
  3. Share of individual OTC markets as a proportion of total OTC market in CEE, 2010      23
  4. Per capita spending on OTC products (€) in CEE countries, 2010      24
  5. Per capita spending on dietary supplements (€) in CEE countries, 2010      24
  6. Value (€ bn) and y-o-y change of the OTC products market in CEE, 2008-2013      25
  7. Average CAGR for OTC markets in the analysed CEE countries for years 2009-2010      25
  8. Average CAGR for OTC markets in the analysed CEE countries for years 2011-2013      26
  9. Market share of drugs and dietary supplements as a proportion of the out-of-the-pocket pharmacy market for plant-based liver protector products in Russia, by value and volume, Q1-Q3 2010      27
  10. Pharmacy sales of OTC products in Russia, by product status, 2010      30
  11. Total sales of OTC products in Russia, by product status, 2010      31
  12. Share of OTC drugs as a proportion of the Russian pharmaceutical market, by value, 2010      31
  13. Share of OTC drugs as a proportion of the Russian out-of-the-pocket market, by value and volume, 2008-2010      32
  14. Share of OTC drugs as a proportion of Russian drug imports, by value and volume, 2009 and 2010      32
  15. Share of OTC drugs as a proportion of the Russian generic drug market, by value, 2008-2010      33
  16. Value (RUB bn) and y-o-y change in the OTC drug market in Russia, 2008-2013      34
  17. Value (RUB bn) and y-o-y change in the dietary supplement market in Russia, 2008-2013      35
  18. OTC drug market in Russia, by main product categories (€ m), 2010      36
  19. Dietary supplement pharmacy market in Russia, by main product categories (€ m), 2010      37
  20. Market share of main dietary supplement categories in Russia, by value, 2010      37
  21. Average prices of OTC drugs per package in Russia ($), 2002-Q1 2011      38
  22. Average prices of dietary supplements per package in Russia ($), 2008-Q1 2011      38
  23. Price ranges of dietary supplements in Russia, by value, imported and domestic, 2010      39
  24. Market share of top 10 best selling OTC drugs in Russia, by sales value, 2010      40
  25. Sales value of top 10 best selling dietary supplements in Russia (€ m), 2010      41
  26. Market share of top 10 best selling dietary supplements in Russia, by sales value, 2010      41
  27. Value of Polish dermocosmetics market (PLN m) and y-o-y change, 2008-2011      47
  28. OTC product market in Poland, by sales channel, 2010      48
  29. Pharmacy sales of OTC products in Poland, by product status, 2010      48
  30. Non-pharmacy sales of OTC products in Poland, by product status, 2010      49
  31. OTC drugs market in Poland, by sales channel, 2010      49
  32. Total sales of OTC products in Poland, by product status, 2010      50
  33. Share of OTC drugs as a proportion of the Polish pharmaceutical market, by value, 2010      50
  34. Value (PLN bn) and y-o-y change in the OTC product market in Poland, 2008-2013      51
  35. Value (PLN m) and y-o-y change in the dietary supplement market in Poland, 2005-2012      52
  36. OTC product market in Poland, by main product categories (€ m), 2010      52
  37. The most popular categories of OTC products in Poland, 2010      53
  38. Value shares of individual therapeutic categories in the non-pharmacy market of medicines in Poland, 2010      54
  39. Shares of individual therapeutic categories of medicines in the number of products in hypermarkets in Poland, 2011      55
  40. Shares of individual therapeutic categories of dietary supplements in the number of products in hypermarkets in Poland, 2011      55
  41. Price per package and pharmacy margins imposed on OTC products in Poland, 2008-2010      56
  42. Average prices of OTC products per package (PLN) and y-o-y change in Poland, 2002-H1 2011      57
  43. The number of Rx-OTC status changes in Poland, 2008-2010      57
  44. Best-selling product categories available from online pharmacies in Poland, 2010      59
  45. Percentage of OTC and Rx prescriptions in Ukraine, by doctor’s specialisation, November 2010      60
  46. Share of individual ATC categories as a proportion of the list of OTC drugs approved in Ukraine, by number of items, December 2010       61
  47. Factors which influence drug purchases at pharmacies in Ukraine, 2011      62
  48. Frequency of OTC drug purchases in Ukraine, 2011      64
  49. Pharmacy sales of OTC products in Ukraine, by product category (UAH m), 2007-2010      65
  50. Pharmacy sales of OTC products in Ukraine, by product category ($ m), 2007-2010      66
  51. Pharmacy OTC product market in Ukraine ($ m), by quarter, and y-o-y increase, Q1 2009-Q4 2010      66
  52. Pharmacy sales of OTC products in Ukraine, by product category (m packages), 2007-2010      67
  53. Year-on-year change in OTC drug and dietary supplement value and volume in Ukraine, in comparison with other product categories, H1 2011      67
  54. Share of OTC drugs as a proportion of the Ukrainian pharmaceutical market, by value, 2010      68
  55. Value (UAH m) and y-o-y change in the OTC drug market in Ukraine, 2008-2013      69
  56. Value of dietary supplement pharmacy sales in Ukraine (UAH m), by foreign and domestic products, 2008-2010      69
  57. Volume of dietary supplement pharmacy sales in Ukraine (m packages), by foreign and domestic products, 2008-2010      70
  58. Value (UAH m) and y-o-y change in the dietary supplement market in Ukraine, 2008-2013      70
  59. Average prices of OTC drugs per package in Ukraine ($), 2007-2010      71
  60. Average prices of cosmetics per package in Ukraine ($), 2007-2010      72
  61. Average prices of dietary supplements per package in Ukraine ($), 2007-2010      72
  62. Factors which influence OTC drug purchases in the Czech Republic, 2011      81
  63. Overweight and obesity of adults in the Czech Republic (% of total population), 2000, 2005, 2008 and 2010      82
  64. Number of OTC drug packages sold in the Czech Republic (million), 2006-Q1 2011      84
  65. Share of OTC products as a proportion of the Czech pharmaceutical market, by value, 2010      84
  66. Value (CZK bn) and y-o-y change the OTC product market in the Czech Republic, 2008-2013      85
  67. OTC product market in the Czech Republic, by main product categories (€ m), 2010      86
  68. Boehringer Ingelheim sales revenues by product groups in Romania (RON m), 2009 and 2010      89
  69. Antibiotice Iasi financial results (RON m), H1 2010 and H1 2011      90
  70. Pharmacy sales of OTC products in Romania, by product status, 2010      93
  71. Share of OTC products as a proportion of the Romanian pharmaceutical market, by value, 2010      94
  72. Value (RON m) and y-o-y change in the OTC products market in Romania, 2006-2013      95
  73. Value (RON m) and y-o-y change in the dietary supplement market in Romania, 2005-2013      95
  74. OTC drug market in Romania, by main product categories (€ m), 2010      96
  75. Opinions about OTC drugs in Hungary (%), 2009      99
  76. Opinions about dietary supplements in Hungary (%), 2009      100
  77. Influence of particular types of advertisements on Hungarians’ drug purchases, Q3 2010      100
  78. Influence of particular types of advertisements on Hungarians’ health and beauty products purchases, Q3 2010      101
  79. Knowledge of expression “functional/curative food” in Hungary, January 2011      101
  80. OTC product market in Hungary, by sales channel, 2010      103
  81. Pharmacy sales of OTC products in Hungary, by product status, 2010      103
  82. Non-pharmacy sales of OTC products in Hungary, by product status, 2010      104
  83. Total sales of OTC products in Hungary, by product status, 2010      104
  84. Share of OTC products as a proportion of the Hungarian pharmaceutical market, by value, 2010      105
  85. Value (HUF bn) and y-o-y change in the OTC product market in Hungary, 2008-2013      106
  86. OTC drug market in Hungary, by main product categories (€ m), 2010      107
  87. Market share of main categories of OTC cold products as a proportion of non-pharmacy sales Hungary, by value, September-December 2009 and 2010      107
  88. Market share of various pharmaceutical forms of OTC cold products as a proportion of pharmacy and non-pharmacy sales in Hungary, by value, September-December 2010      108
  89. Average consumer price per package of main categories of OTC cold products in Hungary (HUF), pharmacy sales, September-December 2009 and 2010      109
  90. Average price per package of selected best-selling analgesics in Hungary (HUF), H2 2010      109
  91. Most popular groups of dietary supplements used by Bulgarians, 2011      113
  92. Estimate of OTC product market in Bulgaria, by sales channel, 2010      114
  93. OTC pharmacy product market in Bulgaria by product category, by value, 2010      115
  94. OTC pharmacy product market in Bulgaria by product category, by volume, 2010      115
  95. Estimated non-pharmacy sales of OTC products in Bulgaria, by product status, 2010      116
  96. Estimated total sales of OTC products in Bulgaria, by product status, 2010      116
  97. Estimated share of OTC drugs as a proportion of the Bulgarian pharmaceutical market, by value, 2010      117
  98. Value (BGN m) and y-o-y change in the OTC product market in Bulgaria, 2009-2013      118
  99. Sales value and volume of dietary supplement pharmacy sales in Bulgaria, 2009-2010      118
  100. OTC drug market in Bulgaria, by main product categories (€ m), 2010      119
  101. Average price per product package of selected leading OTC manufacturers in Bulgaria (BGN), 2010      121
  102. Factors which influenced OTC drug purchases in Slovakia, September 2010      124
  103. Share of OTC products as a proportion of the Slovak pharmaceutical market, by value, 2010      127
  104. Value (€ m) and y-o-y change in the OTC product market in Slovakia, 2008-2013      128
  105. OTC drug market in Slovakia, by main product categories (€ m), 2010      128
  106. Average price per drug package of selected leading OTC manufacturers in Slovakia (€), 2010 and H1 2011      129
  107. Average price per drug package of selected leading OTC drugs in Slovakia (€), H1 2011      130
  108. Total spending on advertising in Russia ($ m) and y-o-y change, healthcare and pharmaceuticals, 2008-2010      135
  109. Breakdown of spending on advertising in Russia, by advertising channel, healthcare and pharmaceuticals, 2008-2010      135
  110. 10 leading TV advertisers of OTC drugs and dietary supplements in Russia, by amount spent, 2010      136
  111. Diod’s advertising spending in Russia, by media category, 2007-2010      137
  112. Shares of individual media in advertising spending of the pharmaceutical industry in Poland, H1 2011      139
  113. Spending on TV advertising of the largest advertisers in the pharmaceutical industry in Poland (PLN m), 2009-H1 2011      140
  114. Spending of pharmaceutical companies on radio advertising in Poland (PLN m), January-February 2010-2011      141
  115. Spending on outdoor advertising (PLN ’000) and change in the pharmaceutical sector in Poland, 2006-Q1 2011      142
  116. Total spending on drug advertising in Ukraine (UAH m) and y-o-y change, 2008-January-July 2011      144
  117. Breakdown of spending on drug advertising in Ukraine, by advertising channel, 2008 – January-July 2011      145
  118. Breakdown of spending on TV drug advertising in Ukraine, by TV channel, 2010      145
  119. 10 leading TV advertisers of OTC drugs in Ukraine, by amount spent, 2010      146
  120. Top 10 brands of OTC drugs in Ukraine in terms of TV advertising spending, by amount spent, 2010      147
  121. Top 10 OTC products in Ukraine in terms of internet advertising spending, by amount spent, 2010      148
  122. Top 10 OTC products in Ukraine in terms of internet advertising spending, by amount spent, Q1 2011      149
  123. Estimated total spending on OTC product advertising in the Czech Republic (€ m), 2009-H1 2011      150
  124. Advertising spending in the pharmaceutical industry in the Czech Republic, by medium, 2010      150
  125. Number of drug advertising permits issued by the National Drug Agency in Romania, 2008-2010      155
  126. Shares of main kinds of advertising as a proportion of the drug advertising budgets in Romania, 2010      155
  127. Leading TV advertisers of OTC products in Bulgaria (BGN m), by amount spent, 2009-2010      159
  128. Krka Group organisation chart, 2011      162
  129. Krka global revenues and net profit (€ m), 2006-2011      162
  130. Krka global sales, by region, 2010      163
  131. Krka sales in selected CEE countries (€ m), 2010 and H1 2011      164
  132. Krka global OTC sales, by product groups, 2010      165
  133. Gedeon Richter global revenues and net profit (€ m), 2006-H1 2011      166
  134. Gedeon Richter global pharmaceutical sales, by country, 2010      168
  135. Pharmstandard sales revenues and net profit (€ m), 2005-H1 2011      169
  136. Share of OTC products as a proportion of Pharmstandard sales revenues, 2010      170
  137. Top 10 Pharmstandard OTC brands, by value, 2010      170
  138. Sopharma global revenues and net profit (€ m), 2008-H1 2011      172
  139. Sopharma export sales, by country and region, Q3 2010      173
  140. US Pharmacia global sales revenues and net profit (€ m), 2004-2009      174
  141. Walmark global turnover (€ m) and y-o-y change, 2003/2004-2010/2011      176
  142. Walmark turnover (€ m) and y-o-y change in Romania, 2006-2011      178
  143. Market share of top 10 manufacturers of OTC drugs in Russia, by value, 2010      179
  144. Sales value of top 10 manufacturers of dietary supplements in Russia (€ m), 2010      180
  145. Market share of top 10 manufacturers of dietary supplements in Russia, by value, 2010      181
  146. Estimated market share of selected top manufacturers of OTC drugs in Poland, by value, 2010      181
  147. Estimated market share of selected top manufacturers of dietary supplements in Poland, by value, 2010      182
  148. Market share of top 10 manufacturers of OTC products in Ukraine, by value, 2010      183
  149. Share of top 10, 25 and 45 companies as a proportion of revenue on the OTC market in Ukraine, by value, 2009-2010      183
  150. Market share of selected top manufacturers of OTC drugs in Ukraine, by value, H1 2011      184
  151. Share of OTC drugs and dietary supplements as a proportion of pharmacy sales value of leading pharmaceutical companies in Ukraine, by value, H1 2011      185
  152. Percentage of OTC and Rx prescriptions in Ukraine, selected manufacturers, November 2010      186
  153. Estimated market share of selected top manufacturers of OTC drugs in the Czech Republic, by value, 2010      187
  154. Estimated market share of selected top manufacturers of dietary supplements in the Czech Republic, by value, 2010      187
  155. Estimated market shares of selected top OTC drug manufacturers in Hungary, by value, 2010      188
  156. Estimated market shares of selected top dietary supplement manufacturers in Hungary, by value, 2010      189
  157. Sales value and volume of top 10 manufacturers of OTC drugs and dietary supplements in Bulgaria, by sales value, 2010      189
  158. Market share of top 10 manufacturers of OTC products in Bulgaria, by value, 2010      190
  159. Market share of selected top manufacturers of OTC products in Bulgaria, by volume, 2010      190
  160. Share of OTC products as a proportion of the sales value of pharmaceutical distributors in Russia, by category of wholesaler, 2010      194
  161. Share of OTC products as a proportion of the sales value of pharmaceutical distributors in Russia, by category of wholesaler, Q1 2011      194
  162. Concentration of pharmaceutical wholesale in Russia, 2006-2010      195
  163. Market share of largest pharmaceutical wholesalers in Russia, by sales value, 2010      195
  164. Protek CV revenues ($ bn) and y-o-y change in Russia, 2006-H1 2011      196
  165. Share of parapharmaceuticals as a proportion of Protek CV’s gross profit in Russia, 2010      197
  166. Share of cosmetics and non-drugs as a proportion of Protek CV’s revenues and number of products in Russia, 2010      197
  167. SIA International revenues ($ bn) and y-o-y change in Russia, 2006-2010      198
  168. Katren revenues ($ bn) and y-o-y change in Russia, 2006-2010      199
  169. Rosta revenues ($ bn) and y-o-y change in Russia, 2007-2010      200
  170. Alliance Healthcare revenues ($ m) and y-o-y change in Russia, 2007/2008-2010/2011      201
  171. Share of parapharmaceuticals as a proportion of the sales value of pharmacy chains in Russia, by category of pharmacy chain, 2010      202
  172. Selected largest pharmacy chains in Russia, by number of outlets, August 2011      203
  173. Market share of selected largest pharmacy chains as a proportion of the pharmacy market in Russia, by sales value, 2010      203
  174. Market share of top 10 pharmacy chains in Russia, by sales value, 2003-2010      204
  175. Market share of selected largest pharmacy chains as a proportion of the pharmacy market in Russia, by sales value, H1 2011      204
  176. 36,6 pharmacy chain expansion in Russia (number of units and y-o-y change), 2003-H1 2011      205
  177. 36,6 sales revenues ($ m) and y-o-y change in Russia, 2004-H1 2011      206
  178. Implozia turnover ($ m) and y-o-y change in Russia, 2009-2010      206
  179. Raduga turnover ($ m) and y-o-y change in Russia, 2009-2010      207
  180. Pharmakor sales revenues ($ m) and y-o-y change in Russia, 2009-2010      208
  181. Rigla sales revenues ($ m) and y-o-y change in Russia, 2006-H1 2011      209
  182. Share of OTC drugs and parapharmaceuticals as a proportion of Rigla sales revenues in Russia, 2010      209
  183. A5 net revenues ($ m) and y-o-y change in Russia, 2007-2014      210
  184. Market shares of the largest players on the pharmaceutical wholesale market in Poland, by sales to pharmacies, H1 2011      214
  185. Neuca group sales revenues (€ m) and y-o-y change in Poland, 2006-H1 2011      215
  186. PGF group sales revenues (€ m) and y-o-y change, 2006-H1 2011      216
  187. Farmacol group sales revenues (€ m) and y-o-y change in Poland, 2006-H1 2011      217
  188. ACP Pharma wholesale revenues (€ m) and y-o-y change in Poland, 2006-H1 2011      218
  189. Turnover on the sale of OTC products in individual pharmacy locations compared to the average pharmacy turnover in Poland (%), 2010      220
  190. Average annual sales of OTC medicines by pharmacies in Poland (PLN ‘000): loyalty programme pharmacies, private pharmacies and chain pharmacies, 2009-2010      221
  191. Selected largest pharmacy chains in Poland, by number of outlets, August 2011      221
  192. ACP Pharma retail sales revenues in Poland (€ m) and y-o-y change, 2006-H1 2011      223
  193. Revenues and net profit/loss of BRL Center in Poland (€ m), 2004-2009      223
  194. Revenues and net profit/loss of Euro Apteka in Poland (€ m), 2003-2009      224
  195. The most popular online pharmacies in Poland, by number of users (real users in ‘000), December 2010      227
  196. Market shares of the largest players on the pharmaceutical wholesale market in Ukraine, by sales to pharmacies, 2010       229
  197. Concentration of pharmaceutical wholesale in Ukraine, market share by sales value, H1 2009-H1 2011      229
  198. BaDM sales ($ m) and y-o-y change in Ukraine, 2009-2010      230
  199. Optima-Pharm sales ($ m) and y-o-y change in Ukraine, 2009-2010      231
  200. Alba Ukraine sales ($ m) and y-o-y change in Ukraine, 2009-2010      231
  201. VVS sales ($ m) and y-o-y change in Ukraine, 2009-2010      232
  202. Fra-M sales ($ m) and y-o-y change in Ukraine, 2009-2010      233
  203. Venta sales ($ m) and y-o-y change in Ukraine, 2009-2010      233
  204. Share of OTC products as a proportion of Venta’s portfolio in Ukraine, 2010      234
  205. Share of OTC products as a proportion of Venta’s sales in Ukraine, by value and volume, 2010      234
  206. Number of pharmacies, pharmacy points and pharmacy kiosks in Ukraine, January 2002-June 2011      236
  207. Number of pharmacy outlets in Ukraine, by category, June 2011      236
  208. Concentration of pharmacy chains in Ukraine and in particular regions, market share by sales value, 2010      237
  209. Market share of selected largest pharmacy chains in Ukraine, by sales value, Q1-Q3 2010      237
  210. Sales revenues of selected largest pharmacy chains in Ukraine (UAH m), Q1-Q3 2010      238
  211. Selected largest pharmacy chains in Ukraine, by number of outlets, August 2011      238
  212. Numbers of medicine distribution licence holders in the Czech Republic, 2004-June 2011      242
  213. Market share of pharmaceutical wholesalers in the Czech Republic, by value, 2002-2010      243
  214. Phoenix Pharma sales revenues (€ m) and y-o-y change in the Czech Republic, February 2005-January 2010      244
  215. Alliance Healthcare sales revenues (€ m) and y-o-y change in the Czech Republic, April 2007-March 2011      245
  216. Share of OTC products as a proportion of Alliance Healthcare revenues in the Czech Republic, H1 2011      245
  217. Pharmos sales revenues (€ m) and y-o-y change in the Czech Republic, 2005-2010      246
  218. Gehe Pharma Prague sales revenues (€ m) and y-o-y change in the Czech Republic, 2006-2010      246
  219. Number of pharmacies and pharmacy points in the Czech Republic, 2000-Q1 2011      247
  220. Selected largest pharmacy chains in the Czech Republic, by number of outlets, August 2011      249
  221. Ceska lekarna sales revenues (€ m) and y-o-y change in the Czech Republic, 2007-2009      250
  222. Revenues and gross profit/loss of EuroPharm in the Czech Republic (€ m), 2006-January 2010      251
  223. Lloyds sales revenues (€ m) and y-o-y change in the Czech Republic, 2006-2010      252
  224. Number of OTC medicines available at places other than pharmacies in the Czech Republic, 2004-2009 and February 2011      254
  225. Market shares of largest players on the pharmaceutical wholesale market in Romania, by sales value to pharmacies and hospitals, 2010      256
  226. Mediplus sales revenues (€ m) and y-o-y change in Romania, 2003-2010      257
  227. FarmExpert sales revenues (€ m) and y-o-y change in Romania, 2006-2011      258
  228. Fildas Trading revenues (€ m) and y-o-y change in Romania, 2005-2010      259
  229. Polisano sales revenues (€ m) and y-o-y change in Romania, 2002-2010      260
  230. Polisano sales breakdown in Romania, by distribution channel, 2003 and 2009      260
  231. Farmexim sales revenues (€ m) and y-o-y change in Romania, 2006-2011      261
  232. Farmexim net profit (€ m) and y-o-y change in Romania, 2009-2011      262
  233. ADM Farm sales revenues (€ m) and y-o-y change in Romania, 2002-2011      263
  234. Number of pharmacies in Romania, by location, 2010      263
  235. Selected largest pharmacy chains in Romania, by number of outlets, October 2011      266
  236. Sensiblu sales revenues (€ m) and y-o-y change in Romania, 2003-2010      267
  237. Farmaplanet revenue (€ m) and y-o-y change in Romania, 2006-2009      267
  238. Catena sales revenues (€ m) and y-o-y change in Romania, 2007-2010      268
  239. Dona sales revenues (€ m) and y-o-y change in Romania, 2007-2010      268
  240. Ropharma sales revenues (€ m) and y-o-y change in Romania, 2007-H1 2011      270
  241. Hermes Pharma revenues (€ m) and y-o-y change in Romania, 2007-2010      270
  242. Help Net sales revenues (€ m) and y-o-y change in Romania, 2002-2011      271
  243. Remedia sales revenues (€ m) and y-o-y change in Romania, 2009-2011      272
  244. Gedeon Richter sales revenues (€ m) and y-o-y change in Romania, 2007-2010      273
  245. Farmacia Richter revenues (€ m) and y-o-y change in Romania, 2007-2010      273
  246. Centrofarm sales revenues (€ m) and y-o-y change in Romania, 2003-H1 2011      274
  247. Estimated market shares of selected largest players on the pharmaceutical wholesale market in Hungary, by sales to pharmacies and hospitals, 2010      277
  248. Hungaropharma sales revenues (€ m) and y-o-y change, 2006-2010      278
  249. Phoenix Pharma sales revenues (€ m) and y-o-y change in Hungary, 2006/2007-2010/2011      279
  250. Viridis Pharma sales revenues (€ m) and y-o-y change in Hungary, 2007-2009      280
  251. Number of pharmacy outlets in Hungary, by category, July 2011      281
  252. Selected largest pharmacy chains in Hungary, by number of outlets, August 2011      283
  253. Pharmacies belonging to Alma pharmacy chain in Hungary, by category, August 2011      284
  254. Share of OTC products as a proportion of Pingvin Patika revenues in Hungary, 2010      285
  255. Number of private wholesalers in Bulgaria, 2007-2010      288
  256. Market shares of largest players on the pharmaceutical wholesale market in Bulgaria, pharmacy and hospital sales, 2010      290
  257. Libra revenues (€ m) and y-o-y change in Bulgaria, 2007-2010      291
  258. Sting revenues (€ m) and y-o-y change in Bulgaria, 2006-2009      291
  259. Sopharma Trading sales revenues and net profit in Bulgaria (€ m), 2007-H1 2011      292
  260. Higia revenues (€ m) and y-o-y change in Bulgaria, 2007-2010      293
  261. Number of private, state-owned and hospital pharmacies in Bulgaria, 2007-2010      294
  262. Average annual turnover of pharmacies in Bulgaria (BGN ‘000) and y-o-y change, 2008-2010      295
  263. Selected largest pharmacy chains in Bulgaria, by number of outlets, August 2011      296
  264. Number of pharmacy outlets operated by SCS Franchise in Bulgaria, by name, August 2011      297
  265. Market share of pharmaceutical wholesalers in Slovakia, by value, 2008-2010      300
  266. Phoenix Pharma sales revenues (€ m) and y-o-y change in Slovakia, February 2005-January 2010      301
  267. Unipharma sales revenues (€ m) and y-o-y change in Slovakia, 2004-2009      301
  268. Med-Art sales revenues (€ m) and y-o-y change in Slovakia, 2005-2009      302
  269. Inforama sales revenues (€ m) and y-o-y change in Slovakia, 2004-October 2010      303
  270. Selected largest pharmacy chains in Slovakia, by number of outlets, August 2011      305
  271. Dr. Max revenues (€ m) and y-o-y change in Slovakia, 2007-2010      306
  272. Comparison of non-pharmacy sales of medicines in CEE countries, 2011      309
  273. Comparison of online sales of medicines in CEE countries, 2011      310
  274. Mean population to pharmacy ratio in selected CEE countries, 2011      311
  275. Countries with the highest GDP growth in the CEE region (%), 2004-2010      314
  276. Countries with the lowest GDP growth in the CEE region (%), 2004-2010      314
  277. Total GDP in CEE countries ($ bn), 2004-2010      315
  278. GDP of CEE countries analysed ($ bn) and its share in total GDP of the region, 2010      315
  279. Countries with the lowest inflation rates in the CEE region (%), 2004-2010      316
  280. Countries with the highest inflation rates in the CEE region (%), 2004-2010      316
  281. Countries with the lowest unemployment rates in the CEE region (%, yearly average), 2004-2010      317
  282. Countries with the highest unemployment rates in the CEE region (%, yearly average), 2004-2010      318
  283. Populations of CEE countries analysed (million of inhabitants), 2010      319
  284. Male life expectancy at birth in CEE countries analysed, 1990 and 2009      320
  285. Female life expectancy at birth in CEE countries analysed, 1990 and 2009      320
  286. Adults of more than 15 years of age who are overweight and obese in CEE countries analysed (% of population), 2010      321
  287. Incidence of alcohol consumption in CEE in comparison with EU average, last 12 months, 2009      321
  288. Incidence of alcohol consumption in selected CEE countries, by country, by incidence, 2009      322
  289. Amount of alcohol drunk in selected CEE countries, by country, by amount, 2009      323
  290. Incidence of smoking among adults (% of population) in selected CEE countries, 2009      324
  291. Incidence of smoking among adults (% of population) in selected CEE countries, by gender, 2009      324

List of tables

  1. Annual average exchange rates used for this report (euro to national currency), 2006-2010      17
  2. Value and volume of OTC drugs market in Russia, 2010      33
  3. Value and volume of dietary supplements pharmacy market in Russia, 2010      35
  4. Leading OTC drugs and dietary supplements as a proportion of the out-of-the-pocket plant-based liver protector market in Russia, in terms of value, Q1-Q3 2010      42
  5. Leading OTC brands by pharmaceutical representative promotions to pharmacists, 2010      63
  6. Average prices per package and per one tablet of best-selling domestic OTC headache drugs in Ukraine, Q1 2011      73
  7. Average prices per package and per one tablet of best-selling foreign OTC headache drugs in Ukraine, Q1 2011      74
  8. Selected best-selling OTC drugs in Ukraine, in terms of value, 2010      75
  9. Selected best-selling OTC drugs in Ukraine, in terms of value, H1 2011      75
  10. Top 10 best-selling OTC domestic headache drugs in Ukraine, in terms of value, Q1 2011      76
  11. Top 10 best-selling OTC foreign headache drugs in Ukraine, in terms of value, Q1 2011      76
  12. Top 10 best-selling dietary supplements in Ukraine, pharmacy sales, in terms of value, 2010      77
  13. Best-selling dietary supplements in individual regions of Ukraine, pharmacy sales, in terms of value, January-August 2010      77
  14. Top 10 best-selling dietary supplements in Ukraine, pharmacy sales, in terms of value, H1 2011      78
  15. Changes in medicinal status (Rx to OTC switch) in the Czech Republic, 2010-H1 2011      87
  16. Best-selling OTC products in the Czech Republic, wholesale sales, by volume, 2010      88
  17. Top two best-selling OTC drugs in Romania, by sales value, Q1 2010 and Q1 2011      97
  18. Top six best-selling OTC drugs in Romania (million of packages), H1 2011      98
  19. Best selling OTC drugs in Hungary, by value, 2010      110
  20. Best selling OTC analgesics in Hungary, by volume, Q3 2010, Q4 2010 and January 2011      111
  21. Best selling OTC analgesics in Hungary, by value, Q3 2010, Q4 2010 and January 2011      111
  22. Average prices of best-selling OTC drugs per package in Bulgaria, 2010      120
  23. Average prices of best-selling dietary supplements per package in Bulgaria, 2010      120
  24. Top 10 best-selling OTC drugs in Bulgaria, by sales value, 2010      121
  25. Selected best-selling OTC drugs in Bulgaria, by sales volume, 2010      122
  26. Top 10 best-selling dietary supplements in Bulgaria, by sales value, 2010      122
  27. Top 10 best-selling OTC drugs in Slovakia, by value, 2010      131
  28. Top 10 best-selling OTC drugs in Slovakia, by value, H1 2011      131
  29. Top 10 best-selling OTC drugs in Slovakia, by volume, 2010      132
  30. Top 10 best-selling OTC drugs in Slovakia, by volume, H1 2011      132
  31. Leading advertisers of OTC products in the Czech Republic, by amount spent, H1 2010 and H1 2011      151
  32. Leading advertisers of dietary supplements in the Czech Republic, by amount spent, 2009-2010      151
  33. 10 top brands of OTC drugs in terms of advertising spending in the Czech Republic, by amount spent, H1 2010 and H1 2011      152
  34. Leading TV advertisers of OTC products in the Czech Republic, by amount spent, 2009-2010      152
  35. Leading radio advertisers of OTC products in the Czech Republic, by amount spent, 2009-2010      153
  36. Leading press advertisers of OTC products in the Czech Republic, by amount spent, 2009-2010      153
  37. Leading outdoor and out-of-home TV advertisers of OTC products in the Czech Republic, by amount spent, 2009-2010      154
  38. Leading advertisers of OTC brands in Hungary, by amount spent, 2010      157
  39. Leading TV advertisers of OTC brands in Hungary, by amount spent, 2010      157
  40. Data on SUKL activity in the area of drug advertising in Slovakia, 2007-2010      160
  41. Top 10 manufacturers of OTC drugs in Slovakia, by value, 2010      191
  42. Top 10 manufacturers of OTC drugs in Slovakia, by value, H1 2011      191
  43. Top 10 manufacturers of OTC drugs in Slovakia, by volume, 2010      192
  44. Top 10 manufacturers of OTC drugs in Slovakia, by volume, H1 2011      192
  45. GDP growth in CEE countries analysed (%), 2004-2010      314
  46. CPI in CEE countries analysed (%), 2004-2010      317
  47. Unemployment rates in CEE countries analysed (%, yearly average), 2004-2010      318
  48. Gross average monthly wages in CEE countries analysed (€), 2004-2010      318
OTC market in Central and Eastern Europe 2011
Comparative analysis and development forecasts for 2011-2013

Choose your version of this product:

Select
language: 		Select
licence: 		     Price: 2500 €
Language / Licence Single 5 Users Corporate Global
English2500€3750€5000€6250€

Compare licences
  • "Single user licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of one computer belonging to the client;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for the individual use of one person only, who is indicated by the client during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
  • "5-user licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of 2 to 5 computers belonging to the organisation indicated by the client while purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for 2 to 5 people who work for the organisation indicated by the client during purchasing process, and who are in the same country as the organisation indicated during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
  • "Corporate licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in the same country as the organisation indicated during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
  • "Global licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers can be located in or outside of the country of the organisation indicated during purchasing process;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in or outside of the country of the organisation indicated during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
    PMR is a member of SIIA's Corporate Content Anti-Piracy Program. Breaking the conditions of our licences will result in a report being sent to SIIA to initiate a piracy investigation and major fees may be imposed by the SIIA as a result. Additionally, for newsletters and online services, it will result in suspension of the subscription with no money refund.